PIK3CA and metastatic neoplasm: We found no significant difference in Ki67 levels in either primary or metastatic tumors when comparing tumors harboring PIK3CA mutations, AKT mutations, or loss of PTEN expression to tumors with no detected pathway alterations (Figure 2B and 2C).